NDAC Veterans Join DSaRM Advisory Panel For DXM Safety Meeting
This article was originally published in The Tan Sheet
The presence of Nonprescription Drug Advisory Committee members as temporary voters on FDA's Drug Safety and Risk Management Advisory Committee brings expertise on OTC issues and a potential industry advocate to the Sept. 14 meeting on dextromethorphan abuse
You may also be interested in...
Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run
Members of an FDA panel tipped their hats to the Consumer Healthcare Product Association's efforts to reduce dextromethorphan abuse, but floated enhancements to the program
A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare